within Pharmacolibrary.Drugs.ATC.J;

model J01DD14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 1.1 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.00020999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 19.98
  );

  annotation(Documentation(
    info ="<html><body><p>Ceftibuten is a third-generation oral cephalosporin antibiotic used primarily for the treatment of infections caused by susceptible strains of bacteria, such as acute bacterial exacerbations of chronic bronchitis, pharyngitis, tonsillitis, and urinary tract infections. It is currently approved for use in several countries and is valued for its once-daily dosing and oral administration route.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Fratoni, AJ, et al., &amp; Asempa, TE (2022). In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination. <i>The Journal of antimicrobial chemotherapy</i> 78(1) 93–100. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkac359&quot;>10.1093/jac/dkac359</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36272135/&quot;>https://pubmed.ncbi.nlm.nih.gov/36272135</a></p></li><li><p>Hernández-Mitre, MP, et al., &amp; Roberts, JA (2024). A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects. <i>Antimicrobial agents and chemotherapy</i> 68(1) e0109923–None. DOI:<a href=&quot;https://doi.org/10.1128/aac.01099-23&quot;>10.1128/aac.01099-23</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38059635/&quot;>https://pubmed.ncbi.nlm.nih.gov/38059635</a></p></li><li><p>Guay, DR (1997). Ceftibuten: a new expanded-spectrum oral cephalosporin. <i>The Annals of pharmacotherapy</i> 31(9) 1022–1033. DOI:<a href=&quot;https://doi.org/10.1177/106002809703100913&quot;>10.1177/106002809703100913</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9296244/&quot;>https://pubmed.ncbi.nlm.nih.gov/9296244</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01DD14;
